October 19, 2020 – Philadelphia, PA – We are pleased to announce that Dr. Diya Ren will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Executive Director of CMC, effective October 19, 2020.

Dr. Ren brings extensive biopharma industry experience in biologic product development. She has led CMC analytical activities strategically from preclinical to BLA. She has wealth of knowledge in cGMP, ICH guidelines, and process and analytical development. She also has demonstrated success in developing and qualifying state-of-the-art biologics analytical methods, and in building strong, engaged team to deliver excellent results for biologics development and regulatory filings.

Most recently, Dr. Ren held the position of Director, Biologic Analytical Development and Process Analytics at Celgene/BMS.  Prior to that, she also held Head of Biologics Analytical Method Development at Gilead Sciences, and Scientist of Protein Analytical Chemistry at Genentech/Roche. Diya obtained her PhD in Analytical Chemistry from Purdue University in 2004.

We are excited to welcome Dr. Ren to WuXi Advanced Therapies!


About WuXi Advanced Therapies (ATU)
The advanced therapies business unit of WuXi AppTec is a Contract Development and Manufacturing Organization (CDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Please visit www.advancedtherapies.com.


Media Contact:
Min Park
Global Head of Marketing
WuXi Advanced Therapies
atu.info@wuxiapptec.com